JP6966428B2 - 副溝結合テイルを有するｄｎａ結合物質 - Google Patents

副溝結合テイルを有するｄｎａ結合物質 Download PDF

Info

Publication number
JP6966428B2
JP6966428B2 JP2018513780A JP2018513780A JP6966428B2 JP 6966428 B2 JP6966428 B2 JP 6966428B2 JP 2018513780 A JP2018513780 A JP 2018513780A JP 2018513780 A JP2018513780 A JP 2018513780A JP 6966428 B2 JP6966428 B2 JP 6966428B2
Authority
JP
Japan
Prior art keywords
substituted
methyl
compound
pyrrole
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018513780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527372A5 (cg-RX-API-DMAC7.html
JP2018527372A (ja
Inventor
ワルデマー プリーベ
リウェイ グオ
アルカディウシュ カジミエスキ
イザベラ フォクト
チャールズ コンラッド
ティモシー マッデン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2018527372A publication Critical patent/JP2018527372A/ja
Publication of JP2018527372A5 publication Critical patent/JP2018527372A5/ja
Application granted granted Critical
Publication of JP6966428B2 publication Critical patent/JP6966428B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
    • C07C13/62—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with more than three condensed rings
    • C07C13/66—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with more than three condensed rings the condensed ring system contains only four rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/244—Anthraquinone radicals, e.g. sennosides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2018513780A 2015-09-16 2016-09-16 副溝結合テイルを有するｄｎａ結合物質 Active JP6966428B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219380P 2015-09-16 2015-09-16
US62/219,380 2015-09-16
PCT/US2016/052144 WO2017049091A1 (en) 2015-09-16 2016-09-16 Dna binding agents with a minor groove binding tail

Publications (3)

Publication Number Publication Date
JP2018527372A JP2018527372A (ja) 2018-09-20
JP2018527372A5 JP2018527372A5 (cg-RX-API-DMAC7.html) 2019-10-24
JP6966428B2 true JP6966428B2 (ja) 2021-11-17

Family

ID=58289623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513780A Active JP6966428B2 (ja) 2015-09-16 2016-09-16 副溝結合テイルを有するｄｎａ結合物質

Country Status (7)

Country Link
US (1) US10358439B2 (cg-RX-API-DMAC7.html)
EP (1) EP3350145B1 (cg-RX-API-DMAC7.html)
JP (1) JP6966428B2 (cg-RX-API-DMAC7.html)
CN (1) CN108368006B (cg-RX-API-DMAC7.html)
AU (1) AU2016323777B2 (cg-RX-API-DMAC7.html)
PL (1) PL3350145T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017049091A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4433039A4 (en) * 2021-11-17 2025-10-29 Univ Texas WATER-SOLUBLE SALTS OF DNA-BINDING AGENTS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196127A (en) * 1978-06-01 1980-04-01 Research Corporation Anthracyclines
US4288608A (en) * 1978-06-01 1981-09-08 Research Corporation Synthesis of anthracyclines
ZA814722B (en) * 1980-07-18 1982-07-28 Hoffmann La Roche Novel anthracycline glycosides
CA1174669A (en) * 1980-07-18 1984-09-18 Michael J. Broadhurst Anthracycline glycosides
JP2000506899A (ja) * 1996-03-22 2000-06-06 プリーベ，ウォールドマー ドキソルビシン耐性腫瘍に対する高活性を有するビス―アントラサイクリン
GB9812937D0 (en) * 1998-06-16 1998-08-12 Btg Int Ltd Compounds
EP1165578B1 (en) 1999-03-19 2012-02-22 Waldemar Priebe Methods and compositions for the manufacture of c-3' and c-4' anthracycline antibiotics
US7605125B2 (en) * 2002-02-27 2009-10-20 The United States Of America As Represented By The Department Of Health And Human Services DNA-binding polyamide drug conjugates
KR101111477B1 (ko) * 2002-12-03 2012-02-23 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 치료제와 연결된 콜레스테롤을 포함하는 접합체
SE0401066D0 (sv) * 2004-04-22 2004-04-22 Stefan Sjoeberg Chemical Derivatives
PL380561A1 (pl) * 2006-09-05 2008-03-17 Szeja Wiesław Prochem Szeja Sposób otrzymywania pochodnych antracyklin
JP2012520298A (ja) * 2009-03-12 2012-09-06 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド Ｇａｂａに結合したアントラサイクリン−脂質複合体

Also Published As

Publication number Publication date
US20180251454A1 (en) 2018-09-06
WO2017049091A1 (en) 2017-03-23
US10358439B2 (en) 2019-07-23
EP3350145A1 (en) 2018-07-25
JP2018527372A (ja) 2018-09-20
AU2016323777B2 (en) 2021-05-13
CN108368006B (zh) 2023-03-07
AU2016323777A1 (en) 2018-04-12
CN108368006A (zh) 2018-08-03
EP3350145A4 (en) 2019-03-27
EP3350145B1 (en) 2020-09-16
CA2998867A1 (en) 2017-03-23
PL3350145T3 (pl) 2021-05-04

Similar Documents

Publication Publication Date Title
JP7789725B2 (ja) ナノ粒子としてのｔＲＮＡ送達用組成物およびその使用方法
CN108699095B (zh) 用于癌症选择性标记和靶向的触发子可活化代谢糖前体
CN103958502B (zh) 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物
JP6474404B2 (ja) ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用
CN101787064B (zh) 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
KR101990214B1 (ko) 표적 특이적 항암 약물전구체
JP2021102616A (ja) 白金耐性の克服における使用のためのテキサフィリン−白金（ｉｖ）コンジュゲート及び組成物
US11191778B2 (en) Multifunctional linker technology containing an N4 group
WO2019227040A1 (en) Substituted pyridinyl azetidinone derivatives for use in treating cancer and other diseases
JP6966428B2 (ja) 副溝結合テイルを有するｄｎａ結合物質
JP2010507626A (ja) Ｖｅｇｆｒ３阻害剤としての大環状キナゾリン誘導体
JP4814245B2 (ja) 低酸素選択性抗腫瘍剤としてのスルホニルヒドラジンのリン酸含有プロドラッグ
CN103619332A (zh) 阿卡地新衍生物、含阿卡地新衍生物的产品和组合物、它们的治疗用途以及合成阿卡地新衍生物的方法
JP7763828B2 (ja) スルホニルベンズアミド系誘導体及びその複合体、その調製方法並びにその応用
JP7698252B2 (ja) 治療薬の核酸媒介性送達
WO2018067551A1 (en) Texaphyrin and antitumor antibiotic conjugates
CA2998867C (en) Dna binding agents with a minor groove binding tail
US20250009727A1 (en) Water-soluble salts of dna binding agents
HK1259495A1 (en) Dna binding agents with a minor groove binding tail
HK1259495B (en) Dna binding agents with a minor groove binding tail
JP7784556B2 (ja) シアリルラクトースを用いた血液脳関門透過用薬物伝達体
WO2023160543A1 (en) Methods of synthesis and uses of agrimol compounds
JP7428642B2 (ja) 過剰増殖性疾患を処置するためのコーヒー酸誘導体
HK1190069A (en) Acadesine derivatives, products and compositions including same, therapeutic uses thereof, and methods for synthesizing same
WO2011113174A1 (zh) 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210922

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211021

R150 Certificate of patent or registration of utility model

Ref document number: 6966428

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250